APA (7th ed.) Citation

Yang, X., Zhang, Y., Jia, S., Yang, Y., Zhu, J., Li, W., . . . Huang, M. The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: Individual patient data from the Chinese NCC and validation from 26 RCTs. Elsevier.

Chicago Style (17th ed.) Citation

Yang, Xi, Yuanyuan Zhang, Shuangzheng Jia, Yong Yang, Jie Zhu, Wei Li, Lingying Wu, Jusheng An, and Manni Huang. The Value of PFS36 as a Primary Endpoint for Radiotherapy Trials in Patients with LACC: Individual Patient Data from the Chinese NCC and Validation from 26 RCTs. Elsevier.

MLA (9th ed.) Citation

Yang, Xi, et al. The Value of PFS36 as a Primary Endpoint for Radiotherapy Trials in Patients with LACC: Individual Patient Data from the Chinese NCC and Validation from 26 RCTs. Elsevier.